Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ravi P, Kumar SK, Cerhan JR, Maurer MJ, Dingli D, Ansell SM, et al. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J. 2018;8:26.

Article  PubMed  PubMed Central  Google Scholar 

Gutiérrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, De Las Rivas J, Ticona FV, et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia. 2010;24:629–37.

Article  PubMed  Google Scholar 

Bustoros M, Anand S, Sklavenitis-Pistofidis R, Redd R, Boyle EM, Zhitomirsky B, et al. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes. Nat Commun. 2022;13:3449.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Simhal AK, Maclachlan KH, Elkin R, Zhu J, Norton L, Deasy JO, et al. Gene interaction network analysis in multiple myeloma detects complex immune dysregulation associated with shorter survival. Blood Cancer J. 2023;13:175.

Article  PubMed  PubMed Central  Google Scholar 

Greipp PR, Miguel JS, Durie BGM, Crowley JJ, Barlogie B, Bladé J, et al. International Staging System for multiple myeloma. J Clin Oncol. 2005;23:3412–20.

Article  PubMed  Google Scholar 

Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

D’Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second Revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40:3406–18.

Article  PubMed  Google Scholar 

Maura F, Rajanna AR, Ziccheddu B, Poos AM, Derkach A, Maclachlan K. Genomic classification and individualized prognosis in multiple myeloma. J Clin Oncol. 2024;42:1229–40.

Article  CAS  PubMed  Google Scholar 

Mohyuddin GR, Rubinstein SM, Kumar S, Rajkumar SV, Fonseca R, Abdallah NH, et al. Performance of newer myeloma staging systems in a contemporary, large patient cohort. Blood Cancer J. 2024;14:95.

Article  PubMed  PubMed Central  Google Scholar 

van Beers EH, van Vliet MH, Kuiper R, de Best L, Anderson KC, Chari A, et al. Prognostic validation of SKY92 and its combination with ISS in an independent cohort of patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2017;17:555–62.

Article  PubMed  Google Scholar 

Weinhold N, Heuck CJ, Rosenthal A, Thanendrarajan S, Stein CK, Van Rhee F, et al. Clinical value of molecular subtyping multiple myeloma using gene expression profiling. Leukemia. 2016;30:423–30.

Article  CAS  PubMed  Google Scholar 

Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276–84.

Article  CAS  PubMed  Google Scholar 

Kellogg DR. WEE1-dependent mechanisms required for coordination of cell growth and cell division. J Cell Sci. 2003;116:4883–90.

Article  CAS  PubMed  Google Scholar 

Mahajan K, Mahajan NP. WEE1 tyrosine kinase, a novel epigenetic modifier. Trends Genet. 2013;29:394–402.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim H-Y, Cho Y, Kang H, Yim Y-S, Kim S-J, Song J, et al. Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer. Oncotarget. 2016;7:49902–16.

Article  PubMed  PubMed Central  Google Scholar 

Harvey SL, Charlet A, Haas W, Gygi SP, Kellogg DR. Cdk1-dependent regulation of the mitotic inhibitor WEE1. Cell. 2005;122:407–20.

Article  CAS  PubMed  Google Scholar 

Tominaga Y, Li C, Wang R-H, Deng C-X. Murine WEE1 plays a critical role in cell cycle regulation and pre-implantation stages of embryonic development. Int J Biol Sci. 2006;2:161–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koh S-B. The expanding role of WEE1. Cell Signal. 2022;94:110310.

Article  CAS  PubMed  Google Scholar 

Harvey SL, Kellogg DR. Conservation of mechanisms controlling entry into mitosis: budding yeast WEE1 delays entry into mitosis and is required for cell size control. Curr Biol. 2003;13:264–75.

Article  CAS  PubMed  Google Scholar 

Elbæk CR, Petrosius V, Sørensen CS. WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry. Mutat Res. 2020;819–820:111694.

Article  PubMed  Google Scholar 

Heijink AM, Blomen VA, Bisteau X, Degener F, Matsushita FY, Kaldis P, et al. A haploid genetic screen identifies the G1/S regulatory machinery as a determinant of WEE1 inhibitor sensitivity. Proc Natl Acad Sci USA. 2015;112:15160–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aarts M, Sharpe R, Garcia-Murillas I, Gevensleben H, Hurd MS, Shumway SD, et al. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov. 2012;2:524–39.

Article  CAS  PubMed  Google Scholar 

Iorns E, Lord CJ, Grigoriadis A, McDonald S, Fenwick K, Mackay A, et al. Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS ONE. 2009;4:e5120.

Article  PubMed  PubMed Central  Google Scholar 

Slipicevic A, Holth A, Hellesylt E, Tropé CG, Davidson B, Flørenes VA. WEE1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions. Gynecol Oncol. 2014;135:118–24.

Article  CAS  PubMed  Google Scholar 

Magnussen GI, Holm R, Emilsen E, Rosnes AKR, Slipicevic A, Flørenes VA. High expression of WEE1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy. PLoS ONE. 2012;7:e38254.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Do K, Doroshow JH, Kummar S. WEE1 kinase as a target for cancer therapy. Cell Cycle. 2013;12:3159–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matheson CJ, Backos DS, Reigan P. Targeting WEE1 kinase in cancer. Trends Pharmacol Sci. 2016;37:872–81.

Article  CAS  PubMed  Google Scholar 

Ghelli Luserna di Rorà A, Cerchione C, Martinelli G, Simonetti G. A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target. J Hematol Oncol. 2020;13:126.

Article  PubMed  PubMed Central  Google Scholar 

Kong A, Mehanna H. WEE1 inhibitor: clinical development. Curr Oncol Rep. 2021;23:107.

Article  CAS  PubMed  PubMed Central